{
    "Clinical Trial ID": "NCT00320541",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Paclitaxel Plus Bevacizumab (PB)",
        "  paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days",
        "INTERVENTION 2: ",
        "  Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)",
        "  paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by gemcitabine 1500 mg/m2 IV on days 1 and 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Females diagnosed with breast cancer and the cancer has spread to distant areas of the breast or organs.",
        "  Must be able to measure the disease by specific medical parameters",
        "  May have received breast cancer treatment in the early stage of the disease",
        "  May be restricted in physically strenuous activity but able to carry out light work.",
        "  Must have adequate organ function as seen in blood test results.",
        "Exclusion",
        "  Criteria:",
        "  Cancer that has spread to the brain.",
        "  Unstable heart problems",
        "  Unstable high blood pressure.",
        "  Breast cancer treatment after the disease has considered to spread to other areas or organs.",
        "  Unable to agree with the requirements of the study"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Overall Response Rate (ORR)",
        "  Response defined per Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. ORR was defined as the proportion of participants who achieved a best response of either CR or PR. ORR=number of participants with CR or PR/number of participants qualified for tumor response analysis (per-protocol population).",
        "  Time frame: baseline & every 2 cycles (approximately 8 weeks) of treatment to measured progressive disease (PD) & post-therapy until PD or other therapy initiated (up to 35 months)",
        "Results 1: ",
        "  Arm/Group Title: Paclitaxel Plus Bevacizumab (PB)",
        "  Arm/Group Description: paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days",
        "  Overall Number of Participants Analyzed: 94",
        "  Mean (95% Confidence Interval)",
        "  Unit of Measure: proportion of responders  0.489        (0.385 to 0.595)",
        "Results 2: ",
        "  Arm/Group Title: Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)",
        "  Arm/Group Description: paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by gemcitabine 1500 mg/m2 IV on days 1 and 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days",
        "  Overall Number of Participants Analyzed: 92",
        "  Mean (95% Confidence Interval)",
        "  Unit of Measure: proportion of responders  0.587        (0.479 to 0.689)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 27/94 (28.72%)",
        "  Anaemia 2/94 (2.13%)",
        "  Febrile neutropenia 2/94 (2.13%)",
        "  Leukopenia 1/94 (1.06%)",
        "  Neutropenia 0/94 (0.00%)",
        "  Thrombocytopenia 1/94 (1.06%)",
        "  Arrhythmia 0/94 (0.00%)",
        "  Atrial fibrillation 0/94 (0.00%)",
        "  Cardiac failure congestive 0/94 (0.00%)",
        "  Cardiomyopathy 0/94 (0.00%)",
        "  Pericardial effusion 0/94 (0.00%)",
        "  Tachycardia 0/94 (0.00%)",
        "Adverse Events 2:",
        "  Total: 36/93 (38.71%)",
        "  Anaemia 2/93 (2.15%)",
        "  Febrile neutropenia 9/93 (9.68%)",
        "  Leukopenia 3/93 (3.23%)",
        "  Neutropenia 4/93 (4.30%)",
        "  Thrombocytopenia 1/93 (1.08%)",
        "  Arrhythmia 1/93 (1.08%)",
        "  Atrial fibrillation 1/93 (1.08%)",
        "  Cardiac failure congestive 3/93 (3.23%)",
        "  Cardiomyopathy 2/93 (2.15%)",
        "  Pericardial effusion 1/93 (1.08%)",
        "  Tachycardia 1/93 (1.08%)"
    ]
}